^
Association details:
Biomarker:IDH2 mutation
Cancer:Sarcoma
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas

Excerpt:
Ten patients with IDH1/2-mutant tumors by next-generation sequencing were treated with olaparib 300 mg twice daily...Three of five patients with chondrosarcomas had clinical benefit, including one patient with a partial response and two with stable disease lasting > 7 months...PARP inhibition in patients with IDH1/2-mutant chondrosarcoma.